Open Access Peer-reviewed Hypothesis

Effects of Pinus massoniana bark extract on the size of HeLa cells via Nesprin-2 pathway

Article Sidebar

Hypothesis of PMBE
Download PDF
Submitted   Mar 20, 2020
Published   Jun 25, 2020
Issue    Vol 2 (2020)
DOI   10.25082/CCR.2020.01.003

Views

3370

Downloads

1530

Citations

PlumX Metrics

Main Article Content

Xiaolu Zhang
1. Department of Regenerative Medicine, Tongji University School of Medicine, Shanghai, 200092, China; 2. Department of gynecology and obstetrics, Jinshan Hospital of Fudan University, Shanghai 201508, China
Mengqi Li
Department of Regenerative Medicine, Tongji University School of Medicine, Shanghai, 200092, China
Yingya Li
1. Department of Regenerative Medicine, Tongji University School of Medicine, Shanghai, 200092, China; 2. Center of Reproductive Medicine, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 201204, China
Jiao Feng
1. Department of Regenerative Medicine, Tongji University School of Medicine, Shanghai, 200092, China; 2. Department of Gastroenterology, Shanghai Tenth Peoples Hospital, Tongji University School of Medicine, Shanghai 200072, China
Yingyu Cui corresponding author
1. Department of Regenerative Medicine, Tongji University School of Medicine, Shanghai 200092, China; 2. Key Laboratory of Arrhythmias of the Ministry of Education of China (Tongji University), Shanghai 200120, China; 3. Institute of Medical Genetics, Tongji University School of Medicine, Shanghai 200092, China

Abstract

Proanthocyanidins (PAs) is the main constituent of Pinus massoniana bark extract (PMBE). PMBE was reported to induce cell cycle arrest and apoptosis in HeLa cells. During cell division, cells synthesize protein in G1 and G2 phases and replicate chromatin in S phase during interphase, which increases cell mass. Nesprins, a kind of protein encoded by syne gene, is a vital part of cytoskeleton and plays a role in cell cycle progress and cell division. HeLa cells were used as a model to examine effects of PMBE on cell growth and Nesprins expression with MTT assay and RT- PCR analysis, respectively. The cell size was evaluated by counting the cell number in a fixed area under microscope. The results showed that the size of survival HeLa cells in PMBE-treated group was obviously larger than that of those in control group (p = 0.00223, < 0.01), while the mRNA expression level of Nesprin-2 decreased significantly in PMBE-treated group (p = 0.0201, < 0.05). On this account, we put forward a hypothesis that PMBE inhibits the expression of syne-2, which leads to the decrease of Nesprin-2 and further results in the size increase of HeLa cells.

Keywords
Proanthocyanidins (PAs), Pinus massoniana bark extract (PMBE), Cell size, HeLa cells, Nesprins

Article Details

Supporting Agencies
This project was funded by National University Students Innovation Training Program, grant number: 1500107070; Yangfan Project of Tongji University School of Medicine, grant number: 2012YF05; Fundamental Research Funds for the Central Universities, grant number: 22120180190 and Shanghai Educational Research Project grant number: C19154.
How to Cite
Zhang, X., Li, M., Li, Y., Feng, J., & Cui, Y. (2020). Effects of Pinus massoniana bark extract on the size of HeLa cells via Nesprin-2 pathway. Current Cancer Reports, 2(1), 41-47. https://doi.org/10.25082/CCR.2020.01.003
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

References

  1. Cui YY, Xie H andWang JF. Potential biomedical properties of Pinus massoniana bark extract. Phytotherapy Research, 2005, 19(1): 34-38. https://doi.org/10.1002/ptr.1619
  2. Cui YY, Xie H, Qi KB, et al. Effects of Pinus massoniana bark extract on cell proliferation and apoptosis of human hepatoma BEL-7402 cells. World Journal of Gastroenterology, 2005, 11(34): 5277-5282. https://doi.org/10.3748/wjg.v11.i34.5277
  3. Yang ZQ, Chen H, Tan JH, et al. Cloning of three genes involved in the flavonoid metabolic pathway and their expression during insect resistance in Pinus massoniana Lamb. Ge-netics & Molecular Research, 2016, 15(4): gmr15049332. https://pubmed.ncbi.nlm.nih.gov/28081282
  4. Zeng YX,Wang S,Wei L, et al. Proanthocyanidins: Components, Pharmacokinetics and Biomedical Properties. American Journal of Chinese Medicine, 2020, 48(4): 813-869. https://doi.org/10.1142/S0192415X2050041X
  5. Wu CL, Feng DR, Ma HL, et al. Effect of Pinus massoniana bark extract on IFN- -induced ICAM-1 expression in Ha- CaT human keratinocytes. Journal of Ethnopharmacology, 2009, 122 (1): 48-53. https://doi.org/10.1016/j.jep.2008.11.024
  6. Feng J, Zhang XL, Li YY, et al. Pinus massoniana Bark Extract: Structure-Activity Relationship and Biomedical Potentials. The American Journal of Chinese Medicine, 2016, 44(8): 1559-1577. https://doi.org/10.1142/S0192415X16500877
  7. Xu S, Zhang S, Wang X, et al. Effect of Pinus massoniana Lamb. bark extract on lytic cycle of Epstein-Barr virus. Indian Journal of Experimental Biology, 2012, 50(10): 708- 713. https://doi.org/10.7440/colombiaint83.2015.04
  8. Mao P, Zhang E, Chen Y, et al. Pinus massoniana bark extract inhibits migration of the lung cancer A549 cell line. Oncology Letters, 2017, 13(2): 1019-1023. https://doi.org/10.3892/ol.2016.5509
  9. Ma H, Liu B, Feng D, et al. Pinus massoniana bark extract selectively induces apoptosis in human hepatoma cells, possibly through caspase-dependent pathways. International Journal of Molecular Medicine, 2010, 25(5): 751-759. https://pubmed.ncbi.nlm.nih.gov/20372819
  10. Li YY, Feng J, Zhang XL, et al. Pine bark extracts: nutraceutical, pharmacological, and toxicological evaluation. Journal of Pharmacology & Experimental Therapeutics, 2015, 353(1): 9-16. https://doi.org/10.1124/jpet.114.220277
  11. Lin BW, Gong CC, Song HF, et al. Effects of anthocyanins on the prevention and treatment of cancer. British Journal of Pharmacology, 2017, 174(11): 1226-1243. https://doi.org/10.1111/bph.13627
  12. Wu DC, Li S, Yang DQ, et al. Effects of Pinus massoniana bark extract on the adhesion and migration capabilities of HeLa cells. Fitoterapia, 2011, 82(8): 1202-1205. https://doi.org/10.1016/j.fitote.2011.08.008
  13. Li YY, Feng J, Zhang XL, et al. Effects of Pinus massoniana bark extract on the invasion capability of HeLa cells. Journal of Functional Foods, 2016, 24: 520-526. https://doi.org/10.1016/j.jff.2016.04.030
  14. Zhao CX, Cui YY and Chen YH. Progress of The Research on Nesprins. Progress in Biochemistry and Biophysics, 2014, 41(4): 337-344. http://www.pibb.ac.cn/pibbcn/ch/reader/create pdf.aspx?fil e no=20130186&flag=1&journal id=pibbcn
  15. Zhou C, Rao L, Shanahan CM, et al. Nesprin-1/2: roles in nuclear envelope organisation, myogenesis and muscle disease. Biochemical Society Transactions, 2018, 46(2): 311- 320. https://doi.org/10.1042/BST20170149
  16. Elvira I, Alessia C, Robin F, et al. LINC complex-Lis1 interplay controls MT1-MMP matrix digest-on-demand response for confined tumor cell migration. Nature Communications, 2018, 9(1): 1-13. https://doi.org/10.1038/s41467-018-04865-7
  17. King SJ, Nowak K, Suryavanshi N, et al. Nesprin-1 and nesprin-2 regulate endothelial cell shape and migration. Cytoskeleton, 2014, 71(7): 423-434. https://doi.org/10.1002/cm.21182
  18. Matsumoto A, Hieda M, Yokoyama Y, et al. Global loss of a nuclear lamina component, lamin A/C, and LINC complex components SUN1, SUN2, and nesprin-2 in breast cancer. Cancer Medicine, 2015, 4(10): 1547-1557. https://doi.org/10.1002/cam4.495
  19. Schneider M, Lu W, Neumann S, et al. Molecular mechanisms of centrosome and cytoskeleton anchorage at the nuclear envelope. Cellular & Molecular Life Sciences Cmls, 2011, 68(9): 1593-1610. https://doi.org/10.1007/s00018-010-0535-z
  20. Bj¨orklund M. Cell size homeostasis: Metabolic control of growth and cell division. Biochimica Et Biophysica Acta Molecular Cell Research, 2019, 1866(3): 409-417. https://doi.org/10.1016/j.bbamcr.2018.10.002
  21. Ginzberg MB, Kafri R and Kirschner M. On being the right (cell) size. Science, 2015, 348(6236): 771. https://doi.org/10.1126/science.1245075
  22. Dungrawala H, Hua H, Wright J, et al. Identification of new cell size control genes in S. cerevisiae. Cell Division, 2012, 7(24): 1-13. https://doi.org/10.1186/1747-1028-7-24
  23. Horbay R, Boiko N, Shlyakhtina Y, et al. Giant cancer cells: overcoming drug resistance again and again. Total overview, 2012. https://doi.org/10.13140/2.1.3864.4804
  24. Montgomery C, Couch C, Emory CL, et al. Giant Cell Tumor of Bone: Review of Current Literature, Evaluation, and Treatment Options. Journal of Knee Surgery, 2019, 32(4): 331-336. https://doi.org/10.1055/s-0038-1675815
  25. Amend SR, Torga G, Lin KC, et al. Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance. Prostate, 2019, 79(13): 1489-1497. https://doi.org/10.1002/pros.23877
  26. Vitale I, Jema`a M, Senovilla L, et al. Involvement of p38alpha in the mitotic progression of p53(-/-) tetraploid cells. Cell Cycle, 2010, 9(14): 2823-2829. https://doi.org/10.4161/cc.9.14.12254
  27. Yeung YT, Yin S, Lu B, et al. Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization. EBioMedicine, 2018, 28: 51-61. https://doi.org/10.1016/j.ebiom.2018.01.017
  28. Fan P, Li HX, Wu YM, et al. Biological characteristics of paclitaxel-resistance ovarian cancer cell lines and cryopreservation methods. Cancer Research on Prevention and Treatment, 2015, 42(4): 334-339. https://doi.org/10.3971/j.issn.1000-8578.2015.04.004
  29. Liu X, Jia YH, Zhang K, et al. Establishment of crizotinibresistant non-small cell lung cancer cell line NCI-H3122and preliminary study of resistance related miRNAs. Journal of Third Military Medical University, 2016, 38(7): 687- 692. http://aammt.tmmu.edu.cn/Upload/rhtml/201511024.htm
  30. Yvorel V, Patoir A, Casteillo F, et al. PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis. PLoS One, 2017, 12(7): e0180346. https://doi.org/10.1371/journal.pone.0180346
  31. Du JP, Chen P, Fei HX, et al. Establishment of adriamycinresistant and cisplatin-resistant gastric cancer cell lines and assessment on their sustainability of drug resistance. Journal of Gastroenterology and Hepatology, 2007, 16(4): 368-372. https://doi.org/10.4028/0-87849-470-7.369
  32. Gul A, Leylandjones B, Dey N, et al. A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach. American Journal of Cancer Research, 2018, 8(12): 2359-2376. http://www.ajcr.us/files/ajcr0088398.pdf
  33. Wang Y, Yuan BB and Yue TF. Research progress of polyploidy and cancer. Journal of International Obstetrics and Gynecology, 2010, 37(6): 420-426. (In Chinese)
  34. Cui YY. Cancer, mankind’s challenge. Current Cancer Reports, 2019, 1(1): 1-5. https://doi.org/10.25082/CCR.2019.01.001
  35. Robert G and Christopher W. Cancer treatment innovators discover Charles Darwin. Evolution, Medicine, and Public Health, 2019, 2019(1): 108-110. https://doi.org/10.1093/emph/eoz018
  36. DeGregori J and Gatenby R. Darwin’s ideas on evolution drive a radical new approach to cancer drug use. Principle of evolution and natural selection drive a radical new approach to drugs and prevention strategies. Scientific American, 2019, 321(2): 52. https://doi.org/10.1038/scientificamerican0819-52